Source: PR NEWSWIRE

Press Release: Beta-O2 Technologies : Beta-O2's ßAir Bio-artificial Adrenal Device Shows Potential to Treat Adrenocortical Insufficiency and Other Stress-related Disorders

ROSH HAAYIN, Israel, February 19, 2015 /PRNewswire/ -- Beta-O2 announced today the results of a series of pre-clinical studies demonstrating that the company's ßAir Bio-artificial Adrenal device could offer a treatment for adrenocortical insufficiency and other stress-related...

Read full article »
Est. Annual Revenue
$25-100M
Est. Employees
250-500
Yuval Avni's photo - CEO of Beta-O2 Technologies

CEO

Yuval Avni

CEO Approval Rating

69/100

Read more